Early use of a targeted budesonide for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have IgA nephropathy confirmed by a kidney biopsy within the last 3 months
- Your kidney function is at least 30% of normal (eGFR ≥ 30)
- You have significant protein in your urine (≥1 gram per day or a certain ratio)
- You have not used strong immune-suppressing drugs or steroids in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.